Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxalta Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.baxalta.com

Latest From Baxalta Inc.

Recordati's Isturisa Approved For Cushing's In EU

Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.

Approvals Rare Diseases

Blow To Ipsen As FerGene Nabs CEO Meek

The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.

Appointments Leadership

AskBio Knocks Down Enough Hurdles To Raise $235m For Its Gene Therapy Platform

While some companies rushed into gene therapy and exited after a single setback, Asklepios BioPharmaceutical quietly advanced its programs, identifying challenges and overcoming them one at a time. Now, it's ready to advance multiple programs into the clinic.

Financing Gene Therapy

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Baxter BioScience
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Ludwig N Hantson, PhD, Pres. & CEO
    Robert J Hombach, EVP, CF & COO
    John J Orloff, MD, EVP, Head, R&D & CSO
  • Contact Info
  • Baxalta Inc.
    Phone: (224) 940-2000
    One Baxter Pkwy.
    Deerfield, IL 60015
    USA
UsernamePublicRestriction

Register